Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity of the engineered cells.

That was the consensus of academic researchers who attended a two-day workshop on the topic held by NCI on Dec. 10-11...